Similar articles

• [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].

  Wang SJ, Gao ZY, Lu YP, Li YL, You YQ, Zhang LW, Wang LX, Xu H. Wang SJ, et al. Zhonghua Fu Chan Ke Za Zhi. 2012 Nov;47(11):808-12. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 23302119 Chinese.
• Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screening.

  Ryall RG, Callen D, Cocciolone R, Duvnjak A, Esca R, Frantzis N, Gjerde EM, Haan EA, Hocking T, Sutherland G, Thomas DW, Webb F. Ryall RG, et al. Prenat Diagn. 2001 Jul;21(7):553-7. doi: 10.1002/pd.108. Prenat Diagn. 2001. PMID: 11494290
• [Cost effectiveness analysis of prenatal screening of trisomy 21 by maternal serum markers (hCG)].

  Seror V, Moatti JP, Muller F, Le Gales C, Boue A. Seror V, et al. J Gynecol Obstet Biol Reprod (Paris). 1992;21(8):915-22. J Gynecol Obstet Biol Reprod (Paris). 1992. PMID: 1491137 French.
• [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].

  Senat MV, Rozenberg P, Bernard JP, Ville Y. Senat MV, et al. J Gynecol Obstet Biol Reprod (Paris). 2001 Feb;30(1):11-27. J Gynecol Obstet Biol Reprod (Paris). 2001. PMID: 11240502 Review. French. No abstract available.
• [Fetal trisomy 21 risk evaluation by measurement of maternal serum markers].

  Dhondt JL. Dhondt JL. Ann Biol Clin (Paris). 1998 Jul-Aug;56(4):471-5. Ann Biol Clin (Paris). 1998. PMID: 9754284 Review. French. No abstract available.